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1. Introduction 
Duchenne muscular dystrophy (DMD, OMIM #310200) is the most common form of 
muscular dystrophy in childhood, with an incidence of approximately 1 per 3,500 live-born 
males [Emery, 1991]. It is caused by mutations of the DMD gene located on Xp21 which 
codes for dystrophin, a 427-kDa protein that is expressed at the sarcolemma of skeletal 
muscle. The dystrophin gene contains 79 exons, which includes an actin-binding domain at 
the N-terminus, 24 spectrin-like repeat units, a cysteine-rich dystroglycan binding site, and a 
C-terminal domain [Hoffman et al, 1987; Koenig et al, 1988]. The large size of the dystrophin 
gene results in a complex mutational spectrum (>4,700 different mutations) as well as a high 
spontaneous mutation rate [Aartsma-Rus et al, 2006]. Large deletions account for 
approximately 65% of DMD mutations while duplications occur in up to 10% of males with 
DMD. The remaining 25% include small deletions, insertions, point mutations, or splicing 
mutations. About two-thirds of DMD cases are inherited from mothers carrying the 
mutations, with the remaining one-third occurring as spontaneous mutations [Laing, 1993]. 
According to Monaco et al, DMD-causing mutations are typically associated with an out-of-
frame mutation leading to a loss of functional gene product, whereas in-frame mutations 
that allow synthesis of an internally truncated but functional protein result in a milder 
Becker muscular dystrophy (BMD) phenotype [Monaco et al, 1988].  
Dystrophin is an integral component of the dystrophin glycoprotein complex. It stabilizes 
the muscle membrane by bridging the basal lamina of the extracelluar matrix to the inner 
cytoskeleton of the contractile elements [Rybakova et al, 2000]. It also serve as a 
transmembrane signalling complex which is essential for cell survival [Chen et al, 2000]. 
Loss of dystrophin results in excessive membrane fragility, unregulated influx of calcium 
ions into the sarcoplasm, mitochondrial dysfunction, and increased oxidative stress,  leading 
to progressive muscle degeneration, fibrosis, and fatty replacement [Wallace & McNally, 
2009]. Early presenting features in DMD include developmental delay, proximal muscle 
weakness as evident by Gowers’ sign and waddling gait, as well as varying degree of 
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cognitive impairment and learning disability [Fitzpatrick et al, 1986; Leibowitz & Dubowitz, 
1981]. Serum creatine kinase is usually markedly elevated due to on-going muscle damage 
and regenerative failure. Progressive muscle weakness leads to loss of independent 
ambulation by early teens, scoliosis, quadriplegia, respiratory insufficiency, 
cardiomyopathy, and death around the third decade of life. 
Detection of DMD mutations include multiplex polymerase chain reaction (PCR) that 
examines the most commonly deleted regions of the gene, or other molecular genetic assays 
that interrogate all 79 exons, such as multiplex ligation-dependent probe amplification 
(MLPA) and comparative genomic hybridization (CGH) microarray. If the presence of a 
disease-causing deletion or duplication is not identified by a state-of-the-art DNA diagnostic 
technique, complete gene sequencing is needed to define the precise mutational event 
[Baskin et al, 2009; Takeshima et al, 2010]. A muscle biopsy can also be obtained for 
confirmation of dystrophin deficiency by immunostaining plus extraction of cDNA and 
RNA for further genetic testing [Mah et al, 2011]. 
Recent scientific advances have led to potentially new disease modifying treatments for 
many neuromuscular diseases including DMD [Wagner, 2008; Fairclough et al, 2011]. The 
main therapeutic strategies include: a) muscle membrane stabilization and up-regulation of 
compensatory cytoskeleton proteins such as biglycan and utrophin [Amenta et al, 2011; 
Tinsley et al, 2011]; b) enhancement of muscle regeneration via up-regulation of insulin 
growth factor (IGF-1) and modulation of members of transforming growth factor-beta such 
as myostatin [Schertzer et al, 2008; Morine et al, 2010]; c) reduction of the inflammatory 
cascade by selective nuclear factor-kappa B (NF-κB) inhibition [Tang et al, 2010]; and d) gene 
therapy including the use of adeno-associated virus microdystrophin [Trollet et al, 2009], 
nonsense suppression therapy [Welch et al, 2007; Malik et al, 2010], and exon-skipping to 
restore partial dystrophin protein production [Muntoni et al, 2005; van Deutekom et al, 
2007]. Effective treatment of DMD will likely require multiple interventions targeting 
different disease processes, and updated information about DMD clinical trials is available 
at http://www.clinicaltrials.gov. The success of new and emerging therapeutic strategies 
depends on early diagnosis and precise mutational analysis for boys with DMD, the creation 
of a national or global disease-specific patient registries, plus on-going advocacy and 
interdisciplinary collaboration. 
2. Current management strategies 
Until there is a definitive cure for DMD, current treatment strategies focus on promoting 
well-balanced diet and physical activity as tolerated, delaying the onset of complications via 
pharmaceutical treatments, and optimizing health outcomes through appropriate medical 
and psychosocial support. Therapeutic interventions include the use of corticosteroids (such 
as prednisone or deflazacort) for skeletal muscle weakness and afterload reduction (such as 
angiotensin converting enzyme inhibitor or beta-blocker) for cardiomyopathy. 
Corticosteroid therapy offers benefit to DMD boys by improving muscle strength and 
function [Mendell et al, 1989; Griggs et al, 1991], prolonging independent ambulation 
[Biggar et al, 2001; Schara et al, 2001], plus slowing the progression of cardiomyopathy 
[Markham et al, 2008] and scoliosis [Kinali et al, 2007]. As well, the introduction of non-
invasive positive pressure ventilation has prolonged the survival of individuals with DMD 
[Bach & Martinez, 2011].  
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A number of recent publications have provided comprehensive reviews on the diagnosis 
and multidisciplinary management of DMD, including the use of prednisone or deflazacort 
to preserve muscle strength [Bushby et al, 2004; Moxley et al, 2005], optimizing growth and 
development, surveillance for spinal deformities [Muntoni et al, 2006], managing 
respiratory complications [Finder et al, 2004; Birnkrant et al, 2010], and treating 
cardiomyopathy [American Academy of Pediatrics, 2005; Baxter, 2006]. As well, bone health, 
nutrition, learning disability, behaviour problems, access to wheelchair and other adaptive 
technology should be included as part of the comprehensive treatment plan [Bushby et al, 
2010a; Bushby et al, 2010b]. As standard of care guidelines typically focus on medical 
management and there are no systematic strategies to meet the psychosocial needs of boys 
with DMD and their families, the remaining of this paper will present some of our results on 
pediatric HRQOL, parental experience, and family-centered care approach to DMD that 
may help to identify the needs and incorporate psychosocial support strategies into clinical 
practice. We propose the use of a modified Family Needs Survey for DMD (DMD-FNS) to 
help clinicians to address needs and tailor services for each family across the different stages 
of the disease.  
3. DMD and health-related quality of life  
Chronic neurological disorders such as DMD have a significant impact on pediatric 
health-related quality of life (HRQOL) and functional ability. Both medical services and 
community-based programs are often required to address their physical, emotional, 
social, and educational needs. A large prospective study led by Dr. Craig McDonald and 
his colleagues will provide valuable longitudinal data on the natural history of DMD, 
associated HRQOL, and health services utilization; this 5-year study includes more than 
three hundred boys with a confirmed diagnosis of DMD from 20 participating CINRG 
centers in the United States and other international sites (personal communication). Given 
the lack of information on the processes of care and health outcomes of children with 
chronic neurological disabilities in Canada, a brief 3-month cross-sectional pilot survey 
was performed at the Alberta Children’s Hospital, a tertiary pediatric neurosciences 
center in Calgary, Alberta to explore the use of health services and HRQOL among DMD 
and other pediatric neurosciences patients. Specifically, parents of 278 children (165 male, 
mean age = 11  4.5 years) were asked to describe their child’s functional ability, health-
related quality of life (HRQOL), and use of health services including access to medical 
professionals, rehabilitation programs, education, and social support in their 
communities. The children were followed because of chronic neurological diseases 
including brain tumour (n=33), traumatic brain injury (n=23), hydrocephalus (n=46), 
myelomeningocele (n=29), refractory epilepsy (n=89), or neuromuscular disease (n=58), 
including 14 boys with DMD. As part of the study procedure, the parents completed 
questionnaires regarding their socio-demographic status, their experience with 
rehabilitative and supportive services, their child’s functional ability using the Functional 
Independence Measure (FIMTM/WeeFIM®), and their child’s HRQOL using the PedsQLTM 
(version 4.0) generic core.  
The FIM and WeeFIM are designed to measure functional abilities and limitations in 
activities of daily living. The FIM is used for persons seven years of age or older, while the 
WeeFIM is designed for children between six months to seven years in age. Both versions 
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measure independent performance in self-care, sphincter control, transfers, locomotion, 
communication, and social cognition. Response to each of the items ranges from 1 to 7, with 
higher scores indicating more independence. A total score is calculated by combining scores 
from all eighteen items, and ranges from 18 to 126. The psychometric properties of the FIM 
have been described in previous studies [Chau et al, 1994; Msall et al, 1994;  Ottenbacher et 
al, 1997].  
The PedsQL (version 4.0) generic core scale is a self-report multidimensional instrument 
designed by Varni et al to measure pediatric HRQOL [Varni et al, 1999]. The raw score for 
each item is transformed to a 0 to 100 scale, with a higher score indicating better quality of 
life. It has been validated for use in children [Varni et al, 2001]. The study was approved by 
the University of Calgary Conjoint Health Research and Ethics Board.  
Among the 278 children, close to one-half  (49%) had some limitations in daily activities, as 
reflected by their mean total FIM score of 90.6 (SD 34.4, max FIM score = 126). 
Approximately 25% were severely disabled and totally dependent on caregivers for self-
care, sphincter control, and transfer. Nearly 40% of patients received regular (weekly to 
monthly) rehabilitation therapy. The majority of health services were financed by 
government health care program; 73 (27%) families reported additional out-of-pocket 
expenses. As anticipated, the use of supportive health services such as physiotherapy or 
occupational therapy was related to the child’s diagnosis, degree of functional ability, and 
his/her HRQOL (see Table 2). On the other hand, socio-demographic variables such as 
parental age, marital status, education, employment, and place of residence were not 
significantly associated with health services utilization, except that parental income was 
associated with varying degree of funding support from the government.  Only a small 
proportion (32%) of these families had access to regular respite, and the frequency of respite 
correlated with the severity of disability. Having a designated care coordinator was 
consistently associated with increased use of health services (OR 2.3 to 3.4). 
Even though many pediatric neurosciences patients experienced significant functional 
limitations and required rehabilitative services, the majority (83%) of parents in this study 
felt that there was adequate medical, educational and financial support in their 
communities. However, almost half (49%) of the families indicated need for more 
psychosocial support, despite adequate medical, rehabilitative, and educational services. 
Parents from visible minority groups, those with English as a second language, and those 
who reported poor mental health were more likely to express need for more social 
support.  
Overall, the physical and psychosocial HRQOL scores for this group of children were lower 
than published healthy controls; their mean PedsQL physical and psychosocial scores were 
63.2 (SD 30.1) and 65.9 (SD 22.4) respectively (maximum PedsQL score = 100). Children with 
refractory epilepsy had the lowest mean psychosocial scores, while those with DMD and 
other neuromuscular diseases scored lowest on the physical scale (see Table 1). This 
suggests that despite their physical limitations, children with neuromuscular diseases 
enjoyed better HRQOL than those with refractory epilepsy. As seen in a subsequent study, 
children with DMD and other progressive neuromuscular diseases experienced further 
decline in their HRQOL, especially when they required the use of assisted mechanical 
ventilation at home [Mah et al, 2008]. 
 
Psychosocial Support Needs of Families of Boys with Duchenne Muscular Dystrophy 85 
 Mean SD Frequency 
Physical functioning (/100)  
 Neuromuscular Disease 
 Myelomeningocele 
52.49
58.92 
30.59
26.87 
57 
29 
 Hydrocephalus 
 Brain Injury
68.56
85.64 
31.13
21.69 
45 
23 
 Brain Tumour 
 Refractory Epilepsy
83.09
53.99 
20.26
30.81 
33 
88 
Psychosocial functioning (/100)  
 Neuromuscular Disease 
 Myelomeningocele
68.05
69.61 
21.10
18.33 
58 
29 
 Hydrocephalus 
 Brain Injury
68.25
72.32 
23.89
16.63 
45 
23 
 Brain Tumour 
 Refractory Epilepsy
80.96
54.10 
17.90
21.36 
33 
89 
Table 1. Comparison of Pediatric Health-Related Quality of Life Scores among children with 
chronic neurological disorders 
 
Dependent variable Independent variables Odds Ratio Wald’s test p value 95% CI 
1. Utilization of 
Medical 
specialists 
 
Child’s age
Surgery 
Psychosocial HRQOL†
Care coordinator
0.911
2.672 
0.979 
3.407
-2.90
3.29 
-3.13 
4.03
0.004
0.001 
0.002 
0.000
0.855 – 0.970 
1.488 – 4.799 
0.965 – 0.992 
1.877 – 6.184 
2. Utilization of 
Allied Health 
Professionals 
 
Diagnosis
Myelomeningocoele
Hydrocephalus 
Brain injury 
Brain tumor 
Epilepsy 
Child’s age 
FIM‡ score 
Psychosocial HRQOL 
Care coordinator
0.295 
0.069 
0.025 
0.261 
0.207 
0.851 
0.969 
0.978 
2.419
-2.09 
-3.92 
-3.13 
-2.06 
-3.13 
-3.76 
-5.03 
-2.39 
2.26
0.037 
0.000 
0.002 
0.039 
0.002 
0.000 
0.000 
0.017 
0.024
 
0.094 – 0.927 
0.018 – 0.263 
0.002 – 0.251 
0.073 – 0.935 
0.077 – 0.555 
0.783 – 0.926 
0.957 – 0.981 
0.961 – 0.996 
1.124 – 5.207 
3. Utilization of 
Educational 
Services 
FIM score
Psychosocial HRQOL 
Parental education 
Care coordinator
0.975
0.960 
2.521 
3.359
-3.64
-3.69 
2.09 
2.97
0.000
0.000 
0.037 
0.003
0.961 – 0.988 
0.939 – 0.980 
1.060 – 5.998 
1.509 – 7.477 
4. Access to Social 
Support 
FIM score
Care coordinator
0.961
2.294
-6.96
2.62
0.000
0.009
0.950 – 0.972 
1.232 – 4.272 
5. Access to 
Funding Support
Psychosocial HRQOL
Family income
0.977
2.375
-2.46
2.37
0.014
0.018
0.959 – 0.995 
1.160 – 4.864 
† Health-related quality of life 
‡ Functional Independence Measure 
Table 2. Multiple regression analysis of rehabilitation and supportive services utilization by 
children with chronic neurological disorders  
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4. Impact of home mechanical ventilation on HRQOL  
The purpose of this study was to explore the impact of the use of life-sustaining assisted 
technologies such as home mechanical ventilation (HMV) on children and adolescents with 
NMD. We compared the HRQOL and parental stress among pediatric neuromuscular 
patients with or without home mechanical ventilation, and again boys with DMD (n = 24) 
were included as part of the study. Parents completed the Parenting Stress Index or the 
Stress Index for Parents of Adolescents, depending on their child’s age. The Parenting Stress 
Index is a 120-item questionnaire that has been standardized for use with parents of children 
aged 1 month to 12 years [Abidin, 1993]. Each item is rated on a 5-point Likert-type scale 
that ranges from 1 (strongly agree) to 5 (strongly disagree). A Total Stress score, a Child 
Domain score, and a Parent Domain score are calculated from the responses. The 112-item 
Stress Index for Parents of Adolescents is an upward extension of the Parenting Stress Index 
for parents of adolescents aged 12 to 18 years [Sheras et al, 1998]. The Stress Index for 
Parents of Adolescents examines the relationship of parenting stress to adolescent 
characteristics, parent characteristics, the quality of adolescent-parent interactions, and 
stressful life circumstances. A Total Stress score, an Adolescent Domain score, a Parent 
Domain score, an Adolescent-Parent Relationship Domain score and a Life Stress score are 
calculated from the responses. Support for the content, convergent and discriminant validity 
of both versions of the Parental Stress Index is available. The PedsQL (version 4.0) generic 
core was again used to measure the HRQOL of children with neuromuscular disease.  
109 families participated; 19 (17%) of them had a child with neuromuscular disease 
requiring HMV. Relative to healthy children and other chronically ill children, the pediatric 
neuromuscular patients in this study displayed poorer physical and psychosocial HRQOL. 
In addition, children on HMV had significantly lower mean total PedsQL scores than non-
ventilated children (47.9 vs. 61.5 respectively, p=0.013) (see Table 3); the difference was 
likely the consequence of a more severe disease process in children requiring assisted 
ventilation. Furthermore, the opportunities that these children have to be involved in social 
activities outside of home and at school may be limited by the lack of portability of the 
assisted ventilation devices and/or availability of trained caregivers. However, no 
significant difference in mean total stress scores was found between parents of pediatric 
neuromuscular patients with or without HMV. We postulated that these parents had been 
living with the constant demands of caring for their child with neuromuscular disease 
requiring home mechanical ventilation and that over time, these caretaking demands had 
become part of “normal” life and were not identified as creating additional stress.  
 
Mean PedsQL* Scores HMV†
Status
Number Mean Standard 
deviation 
p value 
 
Physical Non-HMV 92 54.85 27.53 0.001 
 HMV user 14 28.82 22.38  
Psychosocial Non-HMV
HMV user
87
13
63.22
51.06
18.89
13.87
0.028 
Total Non-HMV 91 61.54 18.91 0.013 
 HMV user 13 47.93 12.01  
* PedsQL refers to Pediatric Quality of Life Inventory; † HMV refers to Home Mechanical Ventilation  
Table 3. Comparison of Mean Pediatric Quality of Life Inventory scores between Mechanically 
Ventilated and Non-Ventilated Pediatric Neuromuscular Subgroups [Mah et al, 2008a]. 
Reproduced with permission. 
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5. Understanding the parental experience  
In order to further understand parental stress and psychosocial support needs of families 
caring for children with DMD and other neuromuscular diseases (NMD), a qualitative 
research study based on phenomenology was used to describe the experience of parents 
caring for children affected by NMD requiring HMV [Mah et al, 2008]. Data was collected 
from interviews in parents’ homes. The interviews were subsequently modified based on an 
iterative approach to identify the core of the parents’ caregiving experience (see Figure 1).  
 
Fig. 1. Parental experience in caring for a child with neuromuscular disease [Mah et al, 2008b]. 
Reproduced with permission. 
Given the emphasis by parents on providing the best possible care and ensuring optimal 
HRQOL for their child with NMD, the rest of the family unit’s needs including those of the 
siblings, the spouse, and the primary caregiver tended to become secondary priorities. In 
addition being their child’s primary caregivers, parents also took on the various functions of 
health care professionals (HCP) such as nursing and respiratory therapy. Given sufficient 
practice, they soon became experts on their child’s care and the child’s NMD. For most 
parents, the demand of caring for their child with NMD was disruptive to family life; they 
found it hard to spend quality time together. Over time, these demands became part of their 
normal daily routine. One parent summed up major losses such as friendship, income, 
privacy, and personal identity. The loss was not solely related to the child’s NMD and 
declining health, but also due the impact of the parents’ decision to give up their careers, 
passions, and personal desires to meet their child’s needs. Parents lived with uncertainty in 
anticipation of future losses and limitations that their children might experience, as well as 
anxiety as to how their children would react to those losses.  
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Despite a recurring sense of loss, many parents opted to look beyond the negatives and 
focused on the positive aspects of their lives. Most families accepted the reality of caring for 
their child with NMD, and worked through the experience in order to move forward to live 
their lives as best they could. Living for the present helped parents to accept their changed 
lives and to live with the uncertainty that became their “new” normal. Most families also 
lived with the hope that there would be some improvement, a new treatment, or a cure 
around the corner that could benefit their children with NMD.  
The core of the parental experience can be summarized as “being the lifeline” for their child 
with NMD Being the “lifeline” symbolized the vital role and the weight of the responsibility 
that parents had assumed to ensure the survival and well-being of their child with NMD.  The 
core experience conveyed the love and devotion of parents for their child, and their desire for 
their child to live and to enjoy good quality of life despite the physical and sometimes 
cognitive limitations. The lifeline also embodied the mutually dependent and nurturing 
relationship that existed between the parents and their child with NMD. Most parents in this 
study acknowledged that they were receiving as much or more from their child than what 
they were giving to their child. Despite the many challenges and hardships these parents dealt 
with on a daily basis, they could not imagine life without their child, as he/she was also their 
“lifeline.” Therefore, the “lifeline” theme serves as an important reminder to HCP in regards to 
to the parents’ key role in safe guarding their child’s life and ensuring their child’s quality of 
life. Awareness of this reciprocal “lifeline” relationship between the parents and the child with 
NMD should also facilitate the recognition of parents as experts and key partners in decisions 
related to the child’s medical management.  
This study also highlights the importance of support from HCP, extended family, and 
community agencies. As consistent with results by van Kesteren and his colleagues [van 
Kesteren et al, 2001], families with NMD children requiring continuous assisted ventilation 
in our study were more likely to experience increased stress, particularly when support was 
inadequate. Potential gaps in the health care system that were identified by these parents 
included insufficient funding for essential supportive equipment, lack of appreciation for 
the “whole” child and the entire family unit, and unavailability of respite workers due to 
suboptimal wages and manpower shortages in our health regions. Families who perceived a 
lack of support were burdened with the responsibility of being the sole caregivers for their 
child, and might therefore be at higher risk for stress-related illnesses and adverse 
psychological outcomes.  Specific strategies to improve support for these families will 
require greater coordination of services, reliable access to respite personnel, and an 
individualized approach to address each family’s needs and priorities.    
6. Family-centered care approach to DMD  
The management of boys with DMD may benefit from a family centered model of care that 
promotes communication and consensus-building among HCP, administrative staff, and 
community agencies, with each family being an integral part of the interdisciplinary team 
[Ivey et al, 1988]. Accordingly, family-centered practice perceives “the entire family as the 
unit of attention” and provides services in a collaborative fashion based on informed choice, 
in accordance with each individual family’s strengths, needs, and goals. Family centered 
care (FCC) acknowledges the importance of the family in meeting the physical, 
psychosocial, and developmental needs of children [Bissell et al, 2004; American Academy 
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of Pediatrics, 2004]. The premise for a family-centered model of service delivery is based on 
the assumption that “parents know their children best and they want the best for their 
children”[Bamm & Rosenbaum, 2008]. An essential element of this model of care is to align 
the clinical practice with the needs of patients and families, as each family may not want the 
same degree of participation in their health care due to social and cultural factors [Boon et 
al, 2004; Deber, 1994a; Deber, 1994b; Deber et al, 1996]. As needs may change over time, it is 
also important to identify the support needs of individuals and families at different stages of 
the illness [Trivette et al, 1993]. In addition, children thrive within a supportive family and 
community environment. Thus, the purpose of FCC is to empower the caregivers and to 
enhance their well-being in order to maximize positive health and developmental outcomes 
for their children. This model of care reflects a paradigm shift away from the traditional 
paternalistic model of physician-patient relationship towards an equal partnership between 
families and HCP in order to arrive at mutually agreed goals. Early anticipatory guidance 
may help families cope with disease progression (see Table 4) [Dawson & Kristjanson, 2003]. 
The main guiding principle of FCC is to align the clinical practice with the needs of the 
families and to enable each family to be involved in making decisions for their child’s health 
care. In order to accomplish this goal, special attention should be paid to the service 
providers’ interactions with the families as well as the organizational approach to service 
delivery. From an interpersonal level, the practice of FCC will require the service providers 
to: a) show respect for the family’s perspective, values, and cultural diversity; b) identify 
family strengths, needs, and priorities on an on-going basis; c) provide information about 
their child’s condition in a way that matches the family’s needs; d) involve families in 
decision-making; and e) develop services that are flexible to the needs of individual families. 
From an organizational or institutional level, the delivery of family centered services will 
require the managers and policy-makers to provide: a) service coordination and integration 
within and between sectors; b) expedients for family-to-family support; c) family-friendly 
physical environments; d) high quality general and illness-specific information; and e) 
opportunities for family involvement in decision-making at all levels of the organization. 
Previous studies of FCC effectiveness have focused primarily on the impact on FCC 
practices on parental outcomes, such as a reduction in caregivers’ stress, an improvement in 
their overall well-being, or an increase in satisfaction with care [Dunst et al, 2007]. In 2008, 
Dempsey and Keen summarized the findings of 35 studies published during 1993 to 2004 
pertaining to the processes and outcomes of family centered services for children with 
disabilities [Dempsey et al, 2009]. Most of these studies examined health care providers’ 
interpersonal strategies such as the provision of help-giving practices or other processes of 
care. The impact on parent outcomes included: a) a mild to moderate increase in 
psychological well-being; b) an increase sense of empowerment; and c) a greater degree of 
satisfaction with services. The effects on child outcomes were less evident, and included 
some (albeit inconsistent) degree of improvement in child development or health. Recently, 
Moore et al examined the relationship of processes of care to children’s HRQOL [Moore et 
al, 2009]. The study included 187 caregivers of children from the pediatric neurosciences 
clinics at the Alberta Children’s Hospital; 44 (24%) of these children suffered from a 
neuromuscular disease. FCC was found to be a significant predictor of parent-reported 
children’s physical, psychosocial, and total HRQOL, independent of the illness severity. The 
provision of family-centred care practices by service providers had a positive impact on the 
quality of life of children with neurological disorders. 
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Key Stages & 
FCC Strategies 
Early to late ambulatory stage
(4 to 10 years old) 
Early non-ambulatory 
stage (10 to 16 years old) 
Late non-ambulatory 
stage (>16 years old) 
Family 
knowledge: 
Show respect for 
the family’s 
perspective & 
expertise 
 
Identify family’s 
needs, strengths, 
& priorities on an 
on-going basis 
 
Provide 
information that 
matches the 
family’s needs 
 
Facilitate family-
to-family support 
Discuss:
DMD natural history & genetics 
Role of corticosteroids 
Research studies 
 
Genetic counselling referral 
Carrier testing if indicated 
 
Provide written material, 
websites &peer support 
information 
 
Muscular Dystrophy  
Association (MDA) & Parent 
Project contact information 
Discuss:
Nutrition 
Complications of DMD 
(scoliosis, cardiac, and 
respiratory) 
Complications of 
corticosteroids 
Symptoms of nocturnal 
hypoventilation 
Options for long-term 
ventilation assistance  
(i.e. BiPAP, CPAP) 
Medical management of 
cardiomyopathy if present
School & social support 
Respite & financial issues 
Adolescent needs & 
quality of life  
Review previous topics 
Discuss: 
Transition to adult care 
Options for long-term 
ventilation support  
 
Nutritional support 
(i.e. gastrostromy tube) 
 
End-of-life counseling 
and advance medical 
directive 
 
Review previous 
topics 
Professional 
Support 
Involve families in 
decision-making 
 
Develop services 
that are flexible to 
the needs of 
individual families 
 
Provide service 
coordination and 
integration within 
and between 
sectors 
Medical consultations:
Genetics 
Respirology  
Orthopaedics (night splints, 
scoliosis)  
Cardiology  
Neurology / Physiatry 
Ophthalmology (cataracts) 
 
Allied health support: 
Clinic Nurse - Dietician 
Physiotherapist - Psychologist 
Occupational therapy 
Social worker 
MDA community liaison 
Medical consultations 
(as before, plus) 
Endocrinology 
(osteoporosis, 
bisphosphonate therapy) 
 
Teach: 
Chest physiotherapy to 
family 
Breath stacking, cough assist
Seating for wheelchair 
Passive & active exercises 
Medical consultations 
(as before) 
Medical 
Therapy: 
Provide high 
quality general 
and illness-specific 
information 
 
Establish 
opportunities for 
family 
involvement in 
decision-making at 
all levels of the 
organization 
Immunizations:
Varicella vaccine 
Pneumococcal vaccine 
Influenza vaccine 
 
Corticosteroids 
Deflazacort (0.9 mg/kg/d) or 
Prednisone (0.75 mg/kg/d) 
 
Physiotherapy: 
Passive stretching, night splints 
 
Bone health: 
Calcium supplementation 
Vitamin D supplementation 
 
Other: 
Behavioral intervention 
Weight management 
Review previous topics
 
Interventions (as required):
 
Angiotensin converting 
enzyme inhibitor and/ 
or beta-blocker 
(cardiomyopathy) 
 
Diuretics (congestive heart 
failure) 
 
Antibiotics (respiratory 
tract infections) 
 
Sitting ankle-foot orthosis 
 
Scoliosis surgery (pre-op 
Cardiology, Respirology & 
Anaesthesiology consults)
Review previous 
topics 
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Key Stages & 
FCC Strategies 
Early to late ambulatory stage
(4 to 10 years old) 
Early non-ambulatory 
stage (10 to 16 years old) 
Late non-ambulatory 
stage (>16 years old) 
Clinical / 
Laboratory 
Monitoring: 
Create family-
friendly physical 
environments 
 
Weight, height, & blood pressure
Formal muscle function & 
strength test 
ECG, echocardiogram (every  
2 year) 
Pulmonary function testing 
Wrist x-ray for bone age 
Bone densitometry scan 
Same as before, except:
 
ECG, echocardiogram 
(yearly)  
Same as before 
 25-hydroxyvitamin D level
 
Same as before, plus:
PCO2 measurement  
as needed
Same as before 
  
Clinical review: 6 to 12 months 3 to 6 months 1 to 3 months 
Table 4. Summary of Family Centred Care (FCC) Strategies for Duchenne Muscular 
Dystrophy [McMillan et al, 2010]. Reproduced with permission. 
Thus, currently available evidence suggests that interpersonal strategies of FCC are 
positively associated with parental well-being, satisfaction, and empowerment. There is 
limited evidence of positive impact of family centered services on children’s health and 
development. Further studies are needed to determine the key outcome variables as well as 
the longer-term effects of FCC strategies on parent and child outcomes. Subsequent studies 
should also examine if family centered services affect pediatric health outcomes directly or 
indirectly through improving parent outcomes, and how the practice can be incorporated as 
standard of care for children with severe neuromuscular disorders such as DMD. 
7. Challenges related to unmet support needs  
Similar to the reports from caregivers of children with other neuromuscular diseases, parents 
of DMD boys may experience frustration due to poor communication and fragmentation of 
care within the health care system. It is therefore important for clinicians to understand the 
priority support needs of individuals with DMD and their families across different stages of 
the disease. Accordingly, the natural history of DMD can be summarized into five main stages, 
including: a) the pre-symptomatic phase; b) the early ambulatory phase; c) the late ambulatory 
phase; d) the early non-ambulatory phase; and e) the late non-ambulatory phase [Weidner, 
2005]. The purpose of this next study was to explore the unmet support needs of families of 
boys with DMD at different stages of the disease. We adapted the Family Needs Survey 
[Bailey 1990] by adding items specific to DMD, and administered it to a representative sample 
of parents of boys with DMD from two tertiary pediatric neuromuscular clinics in Canada, a 
country where health care is publicly funded. We hypothesized that the number of unmet 
needs might increase over time due to progression of the disease and vary by parental 
sociodemographic characteristics such as ethnicity or education.  
7.1 Methods 
This was a mixed method study with participation from parents of children and youth with 
DMD. For the purpose of this study, individuals were considered to have DMD if they 
fulfilled all of the following criteria: a) onset of weakness before age 5; b) male gender; c) 
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evidence of proximal muscle weakness; d) increased serum creatine kinase; and e) 
confirmed mutation in the dystrophin gene or dystrophic muscle biopsy with marked 
deficiency in dystrophin immunostaining consistent with a diagnosis of DMD. Families with 
limited English comprehension or those who were unable to provide informed consent were 
excluded. Written informed consent from caregivers and assent from children was obtained 
prior to enrolment. The study was approved by the institutional review boards from the two 
participating centers.  
The Family Needs Survey (FNS) was developed by Bailey and Simeonsson as a 
parsimonious approach to identify specific family needs and to elicit parents’ priorities for 
services in children with disabilities [Bailey & Simeonsson, 1990], and it has been adapted 
for use across different cultures [Chen et al; 1994; Hendriks et al, 2000]. The original version 
contained 35 self-report items grouped into seven general categories, including the need for: 
1) information; 2) family and social support; 3) financial support; 4) explaining to others; 5) 
child care; 6) professional support; and 7) community services. Parents who indicate “yes,” 
to each item are given a score of 1, and other responses (no, or not sure) are scored as 0 
[Bailey et al, 2004]. Previous studies have indicated strong inter-item reliability, with a 
reported Cronbach’s alpha coefficient of 0.91 for the total score [Sexton et al, 1992]. Good 
agreement was found between mothers and fathers, and the responses were stable within a 
six-month period [Bailey & Simeonsson, 1988]. Permission from the authors was obtained to 
modify the Family Needs Survey for this study. The DMD Family Needs Survey (DMD-
FNS) contained an additional 31 items exploring disease specific information and support 
needs of families caring for individuals with DMD, reflecting current clinical practice 
guidelines. The maximum score of the DMD Family Needs Survey was 66, with higher 
scores indicating more unmet needs. In addition, families were asked to rate the importance 
of each unmet need on a 5-point Likert scale, with a score of 1 indicating a “somewhat 
important” need, and a score of 5 indicating a “very important” need. The questionnaire 
also included items on the caregivers’ socio-demographic characteristics and their child’s 
current health status.  
The DMD-FNS was reviewed by six paediatric neuromuscular clinic staff (including 
physicians and allied professionals) for content validity, and then piloted with five parents 
of boys with DMD for input regarding the area of needs, the appropriateness of items on the 
scale, the wording, and other content issues. Upon completion of the pilot, a cover letter and 
the revised DMD Family Needs Survey were distributed to the rest of the parents of DMD 
boys followed at the Alberta Children’s Hospital in Calgary, Alberta and the Bloorview Kids 
Rehab in Toronto, Ontario. Both centers provide care for individuals with DMD in a similar 
multidisciplinary team setting, including assessments by paediatrics, social work, nursing, 
occupational therapy, physiotherapy, orthopaedic surgery, dietician, respirology and/or 
cardiology on the same clinic day [McMillan et al, 2010]. 
Parents who consented to participating in the study completed the questionnaire on their 
own and then returned it by mail or in person in a self-addressed and stamped envelope. A 
minimum sample size of 60 responses from the DMD Family Needs Survey was planned, 
with at least 10 to 15 families representing each of the four stages of DMD, including: a) at 
diagnosis (< 8 years); b) near cessation of ambulation (8 - 12 years); c) during adolescence  
(13 - 18 years); d) at advanced stage of the disease (> 18 years). Descriptive statistics were 
used to summarize the characteristics of the study participants and their priority support 
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needs. Categorical variables were expressed as frequencies and percentages, and bivariate 
comparisons were made using Pearson’s chi-square or Fisher’s exact test. Continuous 
variables were reported as means with standard deviations or as medians with interquartile 
ranges if the data was skewed, and comparisons were made using unpaired Student’s t-tests 
or one-way analyses of variance. All tests were two-tailed, and p values less than 0.05 were 
considered to be statistically significant.  
In addition, parents who completed the DMD-FNS at the Bloorview Kids Rehab were 
invited to participate in a focus group meeting. The focus group was an ideal setting to 
verify the survey results, to explore ideas on how to address the identified priority needs, 
and to provide mutual support for the participants based on shared experiences [Kitzinger, 
1995]. Written consent was obtained prior to the start of the meeting. Discussion from the 
focus group was audio-recorded and then transcribed verbatim. The analysis was 
performed in accordance with the phenomenological method of inquiry, by engaging in 
repeated immersions in the data prior to descriptive coding, and then using topic and 
analytic codes to identify themes that were central to the parents’ experience and needs in 
caring for their child with DMD [Coffey & Atkinson, 1996].  
7.2 Results 
A total of 61 (59.8%) out of 102 eligible families participated in the DMD-FNS. Forty-five 
(74%) of the respondents were mothers, and the mean age was 45.3 (standard deviation 7.5, 
range 32-59) years. Fifty-four (89%) respondents were married; 49 (80%) respondents had 
post-secondary education, and the majority (46 families, 75%) were from Bloorview Kids 
Rehab program. The mean age of the boys with DMD was 11.8 (standard deviation 6.4, 
range 1 - 25) years; they were diagnosed at a mean age of 4.2 (standard deviation 2.3, range 0 
to 12) years. Thirty-four (66%) boys were walking independently, 10 (16%) required the use 
of bi-level positive airway pressure ventilatory support, and the majority (51 boys, 84%) 
were on deflazacort as disease modifying treatment for DMD. There was no significant 
difference between the study participants and study non-responders in regards to the 
child’s age, ambulatory status, need for assisted ventilation, or use of corticosteroids. 
7.2.1 Unmet family support needs 
The mean DMD-FNS total score was 25.1 (standard deviation 15.0), reflecting a large number 
of unmet family support needs.  Cronbach alpha for the total score was 0.95, which suggested 
a high level of inter-item reliability. We found no significant differences between the mean 
number of needs and the stage of the disease by age group (see Table 5). The categories with 
the largest numbers of unmet needs overall, and for which a majority of parents expressed 
unmet needs were related to information, financial, and psychosocial supports. All items that 
the majority of families (i.e., >50%) indicated were unmet needs are listed in Table 6. Each of 
these items had mean Likert rating scores greater than 4, confirming that these were 
“important” or “very important” needs for the parents. There were no significant differences 
between the mean number of needs and the child’s characteristics such as age, ambulatory 
status, need for ventilation support, and other co-morbidities such as learning disability, 
behavioural problems, or scoliosis. Similarly, socio-demographic factors including the parent’s 
age, ethnicity, marital status, education, and place of residence (Ontario versus Alberta) were 
not associated with significant differences in the mean number of identified needs. 
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Unmet Needs All ages
(n = 57*)
< 8 yrs
(n = 19)
8 – 12 yrs
(n = 14)
13 – 18 yrs
(n = 8)
>18 yrs 
(n = 16) 
p value 
Information 
Mean (SD†) 11.5 (6.4) 11.8 (6.8) 10.8 (6.2) 14.6 (5.1) 10.2 (6.6) 
 
0.44 
Family and social support
Mean (SD) 4.1 (3.8) 3.3 (4.0) 4.6 (3.2) 4.6 (3.4) 4.4 (4.3) 
 
0.75 
Financial support
Mean (SD) 3.5 (3.0) 2.8 (3.5) 3.9 (2.2) 3.7 (3.0) 4.0 (3.2) 
 
0.63 
Explaining to others
Mean (SD) 1.4 (1.5) 1.9 (1.7) 1.3 (1.3) 1.2 (0.7) 0.8 (1.6) 
 
0.17 
Child care 
Mean (SD) 1.1 (0.9) 0.9 (1.1) 1.4 (0.6) 1.0 (0.8) 1.0 (0.9) 
 
0.56 
Professional support
Mean (SD) 1.3 (1.8) 1.3 (2.4) 1.1 (1.1) 1.2 (1.4) 1.7 (1.8) 
 
0.82 
Community services
Mean (SD) 2.0 (1.3) 2.2 (1.5) 1.6 (1.1) 2.0 (1.2) 2.2 (1.4) 
 
0.51 
Total 
Mean (SD) 24.9 (15.2) 24.2 (18.3) 24.6 (13.2) 28.5 (10.7) 24.4 (15.8) 
 
0.92 
* Four had incomplete responses and were removed from the analyses of variance 
† SD referred to standard deviation of the mean 
Table 5. Comparison of total mean number of unmet needs by different age categories of 
boys with DMD 
 
 
Percent
Number of 
Respondents 
General Information Needs  
Information about services presently available for my child 74† 61 
Information about services for parents and siblings* 74† 61 
How my child will grow and develop 64† 59 
Information about services my child might receive in the future  62 61 
Reading materials or websites about other families who have a child 
like mine 
59 61 
DMD Specific Information Needs  
Improving my child’s bone health* 66† 60 
Issues related to spinal deformity or scoliosis* 62 61 
Helping my child to be more physically active* 61 61 
The diagnosis of DMD and what it means for my child and my family* 54 60 
Stretching exercises, night splints or orthotics* 54 61 
Issues related to my child’s lung function* 54 60 
Use of corticosteroids and/or other treatment* 51 61 
Use of bi-level positive airway pressure or other assisted breathing 
devices* 
51 60 
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Percent
Number of 
Respondents 
Financial Support Needs  
Paying for medications, treatment or equipment that my child needs 56 61 
Paying for complementary or alternative therapies for my child* 54 61 
Paying for expenses related to modifications in our home and or 
vehicle* 
51 61 
Psychosocial Support Needs  
Meeting and talking with other parents who have a child like mine 67† 61 
Helping my child to make new friends* 56 61 
Locating babysitters or respite care providers who are willing and 
able to care for  my child 
53 61 
* New items specific for DMD are marked with an asterix 
† Indicated the top five most frequently expressed needs in the DMD Family Needs Survey 
Table 6. Unmet information, financial and psychosocial support needs identified by the 
majority of the parents of boys with DMD 
7.2.2 Needs across stages of the illness 
Participants of the 3-hour DMD focus group meeting included eight (3 dads, 5 moms) 
parents of boys (aged 6 to 21 years) with DMD. The main interview questions were: 1) When 
you first learned your son had DMD, what did you need? 2) How did your needs change 
over time? The responses of participants confirmed that information, financial support, and 
psychosocial supports were important needs across the course of the illness. However, the 
types and intensity of supports needed varied according to the stage of the illness, and 
according to each family situation. Themes emerged for the different stages of the illness, 
and these are described below. 
7.2.2.1 Needs at diagnosis  
Parents described their needs for information and emotional support at the time of 
diagnosis. They emphasized that the diagnosis should be given by a knowledgeable and 
empathetic physician, and immediate psychosocial support should be available, preferably 
by connecting with other parents who had gone through the same experience. However, 
some families were not ready to discuss their information needs soon after the diagnosis, 
due to the overwhelming sense of grief. One parent expressed it as a need to “take the time to 
grieve over it first.” The ideal time for discussion might occur much later for these families.  
7.2.2.2 Needs during adolescence 
This period is marked by progressive loss of mobility for boys with DMD. Therefore it is not 
surprising that a dominant need during this time is financial assistance for equipment, 
transportation, and modifications to the family home. Parents identified their struggles with 
bureaucracy and the lack of financial support from public and private sources. They 
indicated that there was a lack of coordination and information about services and financial 
support, as articulated by one parent: “There isn’t a single body that can sort of bring all of these 
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things together and say, ‘okay look, this is where you need to go; this is what you need to do, and 
these are the people you need to get money from … All those agencies, none of them talked to each 
other.” Parents talked about how this forced them into an advocacy role in order to get 
necessary supports and services. They reported that lack of coordination and the subsequent 
need for them to act as advocates resulted in much wasted time, time that could be spent 
caring for their family.  
7.2.2.3 Needs at advanced stage of the disease  
At this point, parents’ needs for information and psychosocial supports seemed to decrease. 
Parents of young adults with DMD described how they had accepted the reality that their 
child could die soon.  Despite the relentless progression of the disease, these parents were able 
to offer meaningful support, encouragement, and practical advice to younger families, as 
summed up by one parent: “I think it really teaches you that … the moment is the most important; 
this day is wonderful, … you learn a lot from your child actually, because they have this sort of innate 
strength that is quite remarkable.” 
Across all the stages parents indicated that they were very interested in participating in 
research, particularly if it would eventually lead to a cure. Those that had been actively 
involved in research activities or fundraising indicated that it gave them hope for the future, 
and helped them feel as if they were helping others. 
8. Discussion  
Consistent with previous research, our study found that parents of boys with DMD have 
many unmet needs, despite living in a country like Canada where health care is publically 
funded [Abresch et al, 1998; Buchanan et al, 1979; Firth et al, 1983]. Their needs may be 
unmet due to a lack of awareness or inability of available resources to adequately target 
their children needs. In this study we did not find a significant difference in the mean 
number of unmet needs across key stages of the illness, which suggests that families have 
needs throughout the course of the illness. As well, there was no significant difference in 
the mean number of needs by disease severity or parental socio-demographic 
characteristics.  
Although the number of needs did not vary, the results of the group interview indicated 
that types of needs within the categories of information, financial, and psychosocial 
supports varied according to the stage of the illness and family situation. By using the 
DMD-FNS during clinic visits, health care professionals may be in a better position to 
understand each family’s unique priority needs and strengths, instead of having to second 
guess what they might be or be influenced by clinician’s personal bias [Gibson, 2001; Kinali 
et al, 2007]. The revised DMD-FNS that was used in this study incorporates topics specific to 
the care of individuals with DMD, and therefore may serve as an ideal prompt for parents to 
discuss these issues during their child’s regular clinic visits. For example, it is important to 
acknowledge the frequent use of complementary or alternative therapies and the resultant 
financial burden on families of children with severe neurological disorders such as DMD 
[Soo et al, 2005]. The parents rated each identified need as very important, so the Likert scale 
did not provide additional information and we recommend it be removed from subsequent 
needs surveys for this population.  
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As the families’ ability to cope during the course of the illness may be modified by their 
interaction with HCP, a major implication of our results is that HCP should make it a 
priority to provide information to families about DMD that is accessible and customized to 
their situation [Fitzpatrick & Barry, 1986; Steele, 2002]. A second priority pertains to the 
coordination of community based services to assist families to access financial supports for 
equipment and housing modifications in a timely fashion. A third priority is the provision 
of ongoing psychosocial supports, which may include individual counselling or family peer 
support programs.  
A limitation of the DMD-FNS study relates to the small sample size. The mixed 
methodology compensated for the low numbers by using a group interview to verify and 
extend the results of the mailed survey. Future studies could recruit a larger sample to 
further explore differences across stages of the illness and across family demographics. A 
second limitation was that we relied on parent report and did not directly survey older 
children and youth for their perceived needs. During the pilot we found that most boys in 
the initial pilot phase of the study did not have the ability to work independently through a 
lengthy questionnaire like the DMD Family Needs Survey. However, previous research 
indicates that the needs of adolescents may vary significantly from their parents, and it is 
important to give the youth a voice [Mah et al, 2006]. Future studies could use an 
abbreviated DMD youth survey to clarify the changing needs of adolescents and young 
adults with DMD over time. Lastly, our survey was limited to families of boys who were 
currently living with DMD and may not provide a complete picture of family needs at the 
final stage of the illness. It may be helpful to interview families after their child has passed 
away.   
Parents who participated in the group interview reflected that they appreciated the 
opportunity to share and to meet each other and were glad to participate in a research 
project.  They indicated that participation in research projects gave them hope for the future. 
Based on this experience we recommend that parents of boys with DMD be included in 
future research initiatives as they have an important perspective and stake in the outcomes 
of such research.  
9. Implications for clinical practice  
Individuals with DMD and their families have to adjust to many challenges because of the 
progressive nature of the disease. The family resilience framework developed by Dr. Froma 
Walsh, Co-Founder and Co-Director of the Chicago Center of Family Health, can be applied 
to the neuromuscular population to serve as a guide to target and strengthen key processes 
that will encourage optimal adaptation of children and adolescents with DMD [Walsh, 
2003]. Resilience involves a dynamic process that enables individuals “to withstand and 
rebound from disruptive life challenges, becoming strengthened, and more resourceful” 
[Rolland & Walsh, 2006]. Resilience is not innate or restricted to certain people only, and it 
can be learned over time. A resilience framework for supporting boys with DMD targets on 
strengths rather than problems, partnership instead of paternalism, and families (rather than 
the clinicians) as the center of attention. It acknowledges the family as the unit of operation, 
with tremendous potentials for growth and transformation. Each family in turn has  unique 
perspectives, resources, strengths, and challenges.  
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According to Walsh, the key processes in family resilience focus on: 1) beliefs system, 
including making meaning of adversity, contextualizing distress, having a positive outlook, 
and developing transcendence and spirituality; 2) organization pattern (in partnership with 
community agencies, schools, healthcare, workplace and other larger systems) that provides 
flexibility, connectedness, social and economic resources; 3) communication strategy, with 
emphasis on clarity, open emotional expression, and collaborative problem-solving. 
Relational attributes of this framework include peers, extended family members, and other 
mentors. The goal of the resilience framework is to promote strong and enduring 
relationships, to help shape and sustain them to meet life challenges. 
In practice, integration of the beliefs system should include: a) assessing family network and 
their prior experience; b) providing peers and extended family support; c) establishing 
routines for young children and their siblings; and d) offering genetic counselling to 
alleviate parental guilt. Positive outlook can be fostered by a) presenting research and 
current available supporting treatment as opportunities for hope; b) affirming the child’s 
potentials and encouraging the family to look forward to college and beyond; and c) 
celebrating successes, initiatives, and perseverance, using life examples such as Jesse’s 
Journey and other parent support organizations. In regards to transcendence and 
spirituality, it is helpful for family to: a) see the bigger picture and purpose, as one family 
said that they were “chosen to live a better life”; b) embrace spiritual domain of being 
human, which includes suffering and injustice; c) learn to living with paradox, to make the 
best out of the worst of times; and d) offer spiritual and inspirational support as necessary.   
Using Walsh’s conceptual approach, clinicians may be in a better position to help 
adolescents and their families to gain insight about their illness experience, to appreciate the 
strengths and vulnerabilities of each family member and the emerging adolescent 
developmental needs, and to recognize key family beliefs that explain their illness narratives 
and relationships with healthcare professionals. Clinicians can also foster the development 
of resilience through their direct interactions with DMD patients and their families. The 
discussion regarding the diagnosis and management of DMD should take place with both 
the child/adolescent and parents present, and they should be encouraged to participate in 
all treatment decisions. The treating physician should provide written information about the 
illness and realistic expectations regarding potential benefits of potentially new disease-
modifying therapies. Financial resources including funding for adaptive equipments should 
be offered regardless of parental employment status or family income.  
Parents should encourage their teenagers to meet age-appropriate developmental goals, 
including gradual transfer of decision-making authority over time. A resilience-oriented 
approach also draws upon extended family and peer resources as potential mentors and 
positive role models in mediating adolescent adjustment to DMD. Clinicians can help 
families resolve conflicts, identify coping strategies, develop realistic goals, and seek help 
when needed. Periodic family meetings and multidisciplinary consultations for anticipated 
transitions, including going away for college and/or transfer to adult services, can facilitate 
proactive planning and alleviate unnecessary anxiety. 
10. Conclusion  
DMD is a challenging chronic disease that requires multidisciplinary collaboration of 
healthcare professionals and individualized treatment approach for the adolescent patients 
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and their families. The modified Family Needs Survey for DMD is a useful tool for needs 
assessment, continuing dialogue with families, and tailoring services to address individual 
families’ needs. It may be used as part of a family-centered approach to the care of boys with 
DMD, in order to promote family resilience and their increase their capacity to deal with the 
challenges related to this devastating disease. 
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